Destiny Pharma
      
Skip to content
  • About Us
    • Board of Directors
    • Leadership
    • Scientific Advisory Board
    • Our Values
    • History
  • Pipeline
    • NTCD-M3 for Clostridioides difficile Infections
    • XF-73 Nasal for Post Surgical Infections
    • XF-73 for Dermal Infections
    • SPOR-COV™ for COVID-19
    • XF Research Programs
  • Target Markets
    • Clostridioides difficile Infections
    • Post Surgical Infections
    • Dermal Infections
    • COVID-19
    • Anti-Microbial Resistance
  • Our Technologies
    • Biotherapeutics
      • NTCD-M3
      • SPOR-COV™
    • XF Platform
  • Business Development
  • News and Media
    • Media
    • Events
  • Investors
    • AIM Rule 26
    • Corporate Governance
    • Share Price Information
    • Regulatory News
    • Constitutional Documents
    • Reports & Presentations
    • Advisers / Shareholder Contacts
    • Analyst Coverage
    • Email Alerts
  • Careers
  • Contact

Regulatory News

15 Aug 2019 – Change in Shareholding

Posted on 16/08/2019 by William Rhys-Williams

Information about a recent change can be found here.

Posted in News Regulatory News

Share Price

Latest News

  • 24 March 2023 – Landmark XF-73 Phase 2 data published in US journal 24/03/2023
  • 16 March 2023 – Result of General Meeting and Total Voting Rights 17/03/2023
  • 15 March 2023 – Result of Open Offer 17/03/2023

Events

  • Proactive One2One Investor Forum – 23 March 2023 23/03/2023
  • ECCMID – 15-18 April 2023 27/02/2023

Destiny Pharma

© All rights reserved.

Powered by WordPress

Destiny Pharma plc
Sussex Innovation Centre
Science Park Square
Brighton
BN1 9SB
UK

Tel: +44(0) 1273 704440

Registered Company
No. 3167025
About Us
Pipeline
Target Markets
Our Technologies
Business Development
News
Investors
Contact
Terms of Use
Privacy Statement